Primary data associated with doi: 10.1042/BCJ20220161 (Impact of 100 LRRK2 variants linked to Parkinson’s Disease on kinase activity and microtubule binding)

By Francesca Tonelli, PhD and Elena Purlyte
View Published Dataset

Output Details

Description

Raw immunoblotting data; tabular data for quantifications; numerical data for in vitro assays; immunofluorescence images; Prism files for statistical analysis.

Identifier (DOI)
10.5281/zenodo.6896851
Tags
  • LRRK2
Team
Team Alessi
Program
Collaborative Research Network
Theme
PD Functional Genomics

Meet the Authors

  • Francesca Tonelli, PhD

    Key Personnel: Team Alessi, 

    University of Dundee

  • User avatar fallback logo

    Elena Purlyte

Related Research

End-product inhibition of the LRRK2-counteracting PPM1H phosphatase

PPM1H phosphatase reverses Rab GTPase phosphorylation by LRRK2 in Parkinson's disease. PPM1H binds Rab8A and Rab10 at an allosteric site, inhibiting phosphatase activity. Targeting this site may offer a therapeutic strategy.

View Article

PPM1M, a LRRK2-counteracting, phosphoRab12-preferring phosphatase with potential link to Parkinson’s disease

LRRK2 phosphorylates Rab GTPases linked to Parkinson's disease. PPM1M identified as a phosphatase reversing Rab phosphorylation, crucial in LRRK2 pathway. PPM1M mutation found in Parkinson's patients, suggesting a new therapeutic target.

View Article

GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis

*GPNMB* is linked to Parkinson's Disease as a risk factor, affecting its transcription and protein levels in CSF. Macrophages secrete GPNMB in response to lysosomal stress through lysosomal exocytosis, with LRRK2 influencing its secretion.

View Article
View More Outputs